Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, El Maani K, Cherkaoui S, Al Zemmouri M, Othmani MB, Zamiati S.

Diagn Mol Pathol. 2013 Jun;22(2):112-8. doi: 10.1097/PDM.0b013e318277448e.

PMID:
23628823
2.

Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H.

Cancer. 2001 Nov 15;92(10):2699-708.

PMID:
11745206
3.

Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, Bennani-Othmani M, Sibai H, Itri M, Benchekroun S, Zamiati S.

Diagn Pathol. 2013 Feb 27;8:39. doi: 10.1186/1746-1596-8-39.

4.

TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.

Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC.

Cancer. 2004 Oct 15;101(8):1873-81.

5.
6.
7.

[Pathology of peripheral neuroblastic tumors].

Wang L, He LJ, Shimada H.

Zhonghua Bing Li Xue Za Zhi. 2012 Apr;41(4):283-8. doi: 10.3760/cma.j.issn.0529-5807.2012.04.020. Chinese. No abstract available.

PMID:
22800533
8.

Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.

Okamatsu C, London WB, Naranjo A, Hogarty MD, Gastier-Foster JM, Look AT, LaQuaglia M, Maris JM, Cohn SL, Matthay KK, Seeger RC, Saji T, Shimada H.

Pediatr Blood Cancer. 2009 Oct;53(4):563-9. doi: 10.1002/pbc.22106.

9.

Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.

Altungoz O, Aygun N, Tumer S, Ozer E, Olgun N, Sakizli M.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):113-9.

PMID:
17213019
10.

Peripheral neuroblastic tumours in eastern Denmark 1972-2002.

Zimling ZG, Rechnitzer C, Rasmussen M, Petersen BL.

APMIS. 2007 Jan;115(1):66-74.

PMID:
17223852
11.

Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.

Nakagawa A, Matsuoka K, Okita H, Iwafuchi H, Hori H, Kumagai M.

Pediatr Dev Pathol. 2011 Mar-Apr;14(2):87-92. doi: 10.2350/08-12-0579.1. Epub 2011 Feb 2.

PMID:
21288077
12.

[Study on MYCN gene amplification and CD44 expression in neuroblastoma].

Hu HL, He LJ.

Zhonghua Bing Li Xue Za Zhi. 2004 Aug;33(4):332-6. Chinese.

PMID:
15363318
13.

Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.

Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H.

Pediatr Blood Cancer. 2013 Mar;60(3):363-70. doi: 10.1002/pbc.24238. Epub 2012 Jun 28.

14.

[Prognostic significance of MYCN amplification in children neuroblastic tumors].

Niu H, Xu T, Wang F, Chen Z, Gao Q, Yi P, Xia J.

Zhonghua Bing Li Xue Za Zhi. 2015 Feb;44(2):111-7. Chinese.

PMID:
25916642
15.

MYCN gene amplification in patients with neuroblastic tumors.

Estiar MA, Fazilaty H, Aslanabadi S, Seifi M, Varghaei P, Rezamand A.

Cell Mol Biol (Noisy-le-grand). 2014 Sep 16;60(3):23-8.

PMID:
25231001
16.

Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.

Tanaka S, Tajiri T, Noguchi S, Shono K, Ihara K, Hara T, Suita S.

J Pediatr Surg. 2004 Jan;39(1):63-8.

PMID:
14694373
17.

Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.

Coco S, Defferrari R, Scaruffi P, Cavazzana A, Di Cristofano C, Longo L, Mazzocco K, Perri P, Gambini C, Moretti S, Bonassi S, Tonini GP.

J Pathol. 2005 Nov;207(3):346-57.

PMID:
16178058
18.

Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.

de Buys Roessingh AS, Rougemont AL, Wiesenauer C, Barrette S, Bouron-Dal Soglio D, Lallier M.

Eur J Pediatr Surg. 2008 Dec;18(6):410-4. doi: 10.1055/s-2008-1038923. Epub 2008 Nov 14.

PMID:
19012235
19.

Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.

Tsai HY, Hsi BL, Hung IJ, Yang CP, Lin JN, Chen JC, Tsai SF, Huang SF.

Hum Pathol. 2004 Nov;35(11):1397-403.

PMID:
15668898
20.

Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma).

Lorenzana AN, Zielenska M, Thorner P, Gerrie B, Weitzman S, Squire J.

Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):875-83.

PMID:
9353827

Supplemental Content

Support Center